Please assess the completion status of the following clinical trial:

Trial Title: PPI's and SSRI's Therapy for the Management of NCCP

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Patients should have at least 3 episodes of chest pain per week in the previous 3 months. Meanwhile they should have undergone a comprehensive diagnostic evaluation by cardiologists in order to exclude a cardiac source for their chest pain. Patients recruited in the study should have either a normal coronary angiogram or lack of ischemic heart disease on exercise treadmill or stress thallium testing.~Exclusion Criteria:~The exclusion criteria will be: i) a history of thoracic, esophageal or gastric surgery, ii) primary or secondary esophageal motility disorders, iii) use of non-steroidal anti-inflammatory drugs and aspirin, iv) presence of Barrett's esophagus, erosive esophagitis, peptic stricture and duodenal or gastric ulcer on upper endoscopy, v) eosinophilic esophagitis, vi) underlying psychiatric illness, vii) pregnancy in women, viii) refusal to participate.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GERD with PPI's therapy (Type: NO_INTERVENTION): Patients will abnormal distal acid esophageal exposure will receive PPI twice daily for 8 weeks .
- PPI's and SSRI's therapy (Type: ACTIVE_COMPARATOR): Patients with positive symptom index for chest pain will receive citalopram 20 mg once daily and PPI once daily for 8 weeks.
- SSRI's therapy (Type: ACTIVE_COMPARATOR): Patients with a negative symptom index for chest pain will receive citalopram 20mg once daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).